Replies to post #599852 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

ATLnsider,

The mouse model used checkpoint inhibitors to achieve immune memory. I believe this is only needed when immune surveillance is lacking but since not all that much was known about DCs when the mouse model was set up it made sense to deal with the influx of checkpoint response from treatment instead of focus on spacing. Spacing of treatments is critical and that became understood better after the fact. My research indicated that spacing of treatments would need to be reduced for the Phase 2 portion of the trial and when proposed changes for Phase 2 were made they went with what I expected needed to be done which was no coincidence, it’s what needed to be done based on the science.
The next leg of Direct trialing will knock it out of the park but should be available even now in life threatening conditions because of known safety profile and signal of effect. “The process” stinks in cases like this and is nothing less than murderous. Soooo much learned since 2013. Best wishes.

[Doc logic]

ATLnsider,

One thing I forgot to mention is that if the makers of those other combo drugs go along with the kind of trial design you suggest, which makes sense on the surface based on L trial results, the data created might effectively put them out of business if what I believe is going to happen occurs. Would they risk that without trying to own NWBO first at almost any cost?; ). See why there might be folks trying to keep the price down while also creating the low price buyout narrative by utilizing so many potential “helpers”?; ).
The gradual shift in focus on this board to share price seems geared towards longs who want to come up for air. Linda knows this and is working very hard to create great value before any interim news is announced that might get longs to sell in the low range targets being bandied around here. Better for me to pass the shares on to the next gen and others than sell low to manipulators. Best wishes.